ADAURA, a randomised phase 3 clinical trial, demonstrated a significant disease-free survival benefit in patients with resected stage IB to IIIA EGFR mutation–positive NSCLC treated with adjuvant osimertinib compared those who received placebo [109]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.